JP2017526662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526662A5 JP2017526662A5 JP2017506390A JP2017506390A JP2017526662A5 JP 2017526662 A5 JP2017526662 A5 JP 2017526662A5 JP 2017506390 A JP2017506390 A JP 2017506390A JP 2017506390 A JP2017506390 A JP 2017506390A JP 2017526662 A5 JP2017526662 A5 JP 2017526662A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- compound
- pharmaceutically acceptable
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 47
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 28
- 239000003207 proteasome inhibitor Substances 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 19
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 229940125904 compound 1 Drugs 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 208000034578 Multiple myelomas Diseases 0.000 claims description 12
- 229960001467 bortezomib Drugs 0.000 claims description 12
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 12
- 229960002438 carfilzomib Drugs 0.000 claims description 12
- 108010021331 carfilzomib Proteins 0.000 claims description 12
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229950002736 marizomib Drugs 0.000 claims description 11
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 claims description 11
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 201000010536 head and neck cancer Diseases 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 229960003648 ixazomib Drugs 0.000 claims description 6
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 201000002628 peritoneum cancer Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 5
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 5
- 108010064641 ONX 0912 Proteins 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 5
- 229950005750 oprozomib Drugs 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- 230000005907 cancer growth Effects 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 230000000405 serological effect Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229950001466 delanzomib Drugs 0.000 claims 2
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims 2
- -1 Opurozomibu Chemical compound 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 201000009030 Carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033386P | 2014-08-05 | 2014-08-05 | |
| US62/033,386 | 2014-08-05 | ||
| PCT/US2015/043825 WO2016022697A1 (en) | 2014-08-05 | 2015-08-05 | Drug combinations to treat multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186703A Division JP2020002179A (ja) | 2014-08-05 | 2019-10-10 | 多発性骨髄腫を治療するための薬物の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526662A JP2017526662A (ja) | 2017-09-14 |
| JP2017526662A5 true JP2017526662A5 (OSRAM) | 2018-09-06 |
| JP6892381B2 JP6892381B2 (ja) | 2021-06-23 |
Family
ID=53836256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506390A Active JP6892381B2 (ja) | 2014-08-05 | 2015-08-05 | 多発性骨髄腫を治療するための薬物の組み合わせ |
| JP2019186703A Pending JP2020002179A (ja) | 2014-08-05 | 2019-10-10 | 多発性骨髄腫を治療するための薬物の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186703A Pending JP2020002179A (ja) | 2014-08-05 | 2019-10-10 | 多発性骨髄腫を治療するための薬物の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11065240B2 (OSRAM) |
| EP (1) | EP3177311B1 (OSRAM) |
| JP (2) | JP6892381B2 (OSRAM) |
| KR (1) | KR102634247B1 (OSRAM) |
| CN (1) | CN106573042A (OSRAM) |
| AU (1) | AU2015301097B2 (OSRAM) |
| BR (1) | BR112017002318A2 (OSRAM) |
| CA (1) | CA2957466C (OSRAM) |
| EA (1) | EA034992B1 (OSRAM) |
| MA (1) | MA40457A (OSRAM) |
| MX (1) | MX382904B (OSRAM) |
| UA (1) | UA121482C2 (OSRAM) |
| WO (1) | WO2016022697A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| CA2939546C (en) | 2014-02-14 | 2023-01-17 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
| MA40386A (fr) | 2014-07-31 | 2016-02-04 | Exelixis Inc | Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| CN109069499A (zh) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
| US11401334B2 (en) * | 2017-09-14 | 2022-08-02 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor |
| CA3088200A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
| WO2023222946A1 (en) | 2022-05-18 | 2023-11-23 | Fermion Oy | Process for the preparation of cabozantinib |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6402215B1 (en) * | 1996-05-21 | 2002-06-11 | American Moto Products, Inc. | Vehicle cargo bed extender |
| ES2651730T3 (es) | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| EP1773826A4 (en) | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
| EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
| EP2350011A1 (en) | 2008-11-13 | 2011-08-03 | Exelixis, Inc. | Methods of preparing quinoline derivatives |
| EP2367795A1 (en) | 2008-12-04 | 2011-09-28 | Exelixis, Inc. | Methods of preparing quinoline derivatives |
| CA2758030C (en) | 2009-01-16 | 2019-01-08 | Exelixis, Inc. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| WO2011009095A1 (en) | 2009-07-17 | 2011-01-20 | Exelixis, Inc. | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| MX2012008898A (es) * | 2010-02-03 | 2012-11-06 | Incyte Corp | Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met. |
| MX2012010506A (es) | 2010-03-12 | 2012-10-15 | Exelixis Inc | Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida. |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| TWI619495B (zh) | 2010-07-16 | 2018-04-01 | 艾克塞里克斯公司 | Ｃ-ｍｅｔ調節劑醫藥組合物 |
| WO2012009723A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
| EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| WO2012044574A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
| WO2012071321A1 (en) | 2010-11-22 | 2012-05-31 | Glaxosmithkline Llc | Method of treating cancer |
| CA2826751C (en) | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| MX2013012695A (es) | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| KR20140069133A (ko) | 2011-09-22 | 2014-06-09 | 엑셀리시스, 인코포레이티드 | 골다공증의 치료방법 |
| EP2768796B1 (en) | 2011-10-20 | 2019-11-20 | Exelixis, Inc. | Process for preparing quinoline derivatives |
| MX2014005458A (es) | 2011-11-08 | 2015-04-16 | Exelixis Inc | Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer. |
| WO2013119693A1 (en) * | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Emp2 regulates angiogenesis in cancer cells through induction of vegf |
| CN103304552B (zh) * | 2012-03-09 | 2016-12-28 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| ES2726605T3 (es) | 2012-09-07 | 2019-10-08 | Exelixis Inc | Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón |
| US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
| BR112015023109A2 (pt) | 2013-03-15 | 2018-05-15 | Exelixis Inc | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida |
| JP2016515628A (ja) | 2013-04-04 | 2016-05-30 | エグゼリクシス， インコーポレイテッド | 癌を治療するための複合薬 |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| CA2939546C (en) | 2014-02-14 | 2023-01-17 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
| BR112016024672A2 (pt) | 2014-04-25 | 2021-02-02 | Exelixis, Inc | método para o tratamento de adenocarcinoma de pulmão |
| MA40386A (fr) | 2014-07-31 | 2016-02-04 | Exelixis Inc | Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| US20170224670A1 (en) | 2014-10-14 | 2017-08-10 | Exelixis, Inc. | Drug Combination to Treat Melanoma |
-
2015
- 2015-08-05 BR BR112017002318-0A patent/BR112017002318A2/pt active Search and Examination
- 2015-08-05 MA MA040457A patent/MA40457A/fr unknown
- 2015-08-05 CA CA2957466A patent/CA2957466C/en active Active
- 2015-08-05 AU AU2015301097A patent/AU2015301097B2/en active Active
- 2015-08-05 WO PCT/US2015/043825 patent/WO2016022697A1/en not_active Ceased
- 2015-08-05 KR KR1020177006288A patent/KR102634247B1/ko active Active
- 2015-08-05 EA EA201790312A patent/EA034992B1/ru not_active IP Right Cessation
- 2015-08-05 JP JP2017506390A patent/JP6892381B2/ja active Active
- 2015-08-05 EP EP15750223.8A patent/EP3177311B1/en active Active
- 2015-08-05 UA UAA201702039A patent/UA121482C2/uk unknown
- 2015-08-05 MX MX2017001490A patent/MX382904B/es unknown
- 2015-08-05 CN CN201580042010.4A patent/CN106573042A/zh active Pending
- 2015-08-05 US US15/501,582 patent/US11065240B2/en active Active
-
2019
- 2019-10-10 JP JP2019186703A patent/JP2020002179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526662A5 (OSRAM) | ||
| JP2012153722A5 (OSRAM) | ||
| JP2011515397A5 (OSRAM) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| EA201690322A1 (ru) | Терапевтически активные соединения и способы их применения | |
| JP2015536964A5 (OSRAM) | ||
| JP2017008088A5 (OSRAM) | ||
| JP2010241830A5 (OSRAM) | ||
| JP2016522266A5 (OSRAM) | ||
| JP2016519062A5 (OSRAM) | ||
| JP2010523670A5 (OSRAM) | ||
| NZ628078A (en) | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
| JP2014533299A5 (OSRAM) | ||
| JP2016503414A5 (OSRAM) | ||
| JP2017528475A5 (OSRAM) | ||
| RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2015512943A5 (OSRAM) | ||
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| JP2015509540A5 (OSRAM) | ||
| JP2019534865A5 (OSRAM) | ||
| JP2017507175A5 (OSRAM) | ||
| JP2011516536A5 (OSRAM) |